91AV

Introduction

Day One

• Viral & non-viral vector safety & quality 
• Delivery and dosage challenges for gene therapies 
• Effective testing, characterisation & validation approaches 

• Scalable and cost-effective production processes 
• Balancing speed-to-market and product quality 
• Internal vs external manufacturing

• CAR-T, TCR & Engineered NK cell therapies 
• Applications of gene therapy in clinical research 
• Challenges from clinic to commercialization 

Day Two

• CRISPR, ZFNs, TALENS 
• Translating gene editing to the clinic 
• Standardisation & quality control for gene editing

• Bioassays & analytical chemistry 
• Developing advanced analytical characterization methods 
• Tools to predict patient response to gene therapy 

Useful links

Speakers

• Donna McLaren Orchard Therapeutics, United Kingdom
• Nripen Singh PassageBio, United States
• Simon Briggs Biogen, United Kingdom
• Lisa Kirkwood Novartis, United Kingdom
• Anthony Newcombe Ireland
• Elise Huang UCB, United Kingdom

---

Venue

Congress Centre

Congress Centre, 28 Great Russell Street, London, WC1B 3LS, United Kingdom

Useful links

Committee

• Oxford Global United Kingdom

---

Organised by

Oxford Global

Contact information

Harry Liddiard
Oxford Global
+441865248455
Contact us by email

---